Corcept Therapeutics (CORT) Director David Mahoney Sells Shares

What Happened

• David L. Mahoney, a director of Corcept Therapeutics (CORT), disposed of a total of 103,606 shares in open‑market sales on August 18, 2026, generating roughly $12.25 million in proceeds. The reported blocks were: 4,984 shares at a weighted avg $117.47 ($585,478); 91,167 shares at $118.24 ($10,779,367); 7,055 shares at $118.88 ($838,710); and 400 shares at $119.64 ($47,855). These transactions are sales (not purchases) and therefore do not signal an insider buy.

Key Details

• Transaction date: August 18, 2026; Form 4 filed August 20, 2026 (filed two days after the trades).
• Reported sale prices (weighted averages for each block): $117.47, $118.24, $118.88, $119.64. Footnotes indicate actual execution prices ranged within $116.595–$119.6775 across the blocks.
• Total shares sold: 103,606; estimated proceeds: $12,251,410.
• Ownership after transaction: not specified in the provided filing details.
• Notable footnotes: at least one sale was made pursuant to a prearranged 10b5‑1 trading plan adopted May 11, 2026; weighted‑average price disclosures note ranges for exact sale prices; a power of attorney referenced is on file with the SEC.

Context

• Sales executed under a 10b5‑1 plan are preplanned trades and are generally considered routine rather than an immediate directional signal from the insider. For retail investors, insider purchases typically warrant more attention as potential bullish signals; these filings document significant insider liquidity but do not by themselves explain motivation.